Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuhiro Yamaguchi

Showing results (1-10 of 365) with videos related to

Pageof 37
Sort By:
Statistics in Medicine|June 24, 2004
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancerTakuhiro Yamaguchi, Yasuo Ohashi
Pharmacoepidemiology and Drug Safety|September 7, 2018
Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plansSaeko Hirota, Takuhiro Yamaguchi
Clinical Pharmacology and Therapeutics|December 24, 2019
Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European UnionSaeko Hirota, Takuhiro Yamaguchi
Statistics in Medicine|June 24, 2004
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effectsTakuhiro Yamaguchi, Yasuo Ohashi
Pharmaceutical Statistics|June 8, 2007
Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methodsYutaka Matsuyama, Takuhiro Yamaguchi
The Lancet. Oncology|March 6, 2020
A new standard prophylaxis for emesis caused by cisplatin? - Authors' replyHironobu Hashimoto, Takuhiro Yamaguchi, Masakazu Abe
International Journal of Clinical Oncology|June 28, 2011
Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicinesTakashi Takeda, Takuhiro Yamaguchi, Nobuo Yaegashi
Drug Safety|March 23, 2011
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008Nobuhiro Ooba, Takuhiro Yamaguchi, Kiyoshi Kubota
International Journal of Urology : Official Journal of the Japanese Urological Association|July 19, 2008
A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladderYukio Homma, Takuhiro Yamaguchi, Osamu Yamaguchi
[Nihon Koshu Eisei Zasshi] Japanese Journal of Public Health|March 8, 2005
[A survey on education of epidemiology and biostatistics in nursing programs at Japanese universities]Shiro Tanaka, Takuhiro Yamaguchi, Yasuo ohashi
Pageof 37

Showing results (1-10 of 365) with videos related to

Sort By:
Pageof 37
Statistics in Medicine|June 24, 2004
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancerTakuhiro Yamaguchi, Yasuo Ohashi
Pharmacoepidemiology and Drug Safety|September 7, 2018
Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plansSaeko Hirota, Takuhiro Yamaguchi
Clinical Pharmacology and Therapeutics|December 24, 2019
Timing of Pediatric Drug Approval and Clinical Evidence Submitted to Regulatory Authorities: International Comparison Among Japan, the United States, and the European UnionSaeko Hirota, Takuhiro Yamaguchi
Statistics in Medicine|June 24, 2004
Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effectsTakuhiro Yamaguchi, Yasuo Ohashi
Pharmaceutical Statistics|June 8, 2007
Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methodsYutaka Matsuyama, Takuhiro Yamaguchi
The Lancet. Oncology|March 6, 2020
A new standard prophylaxis for emesis caused by cisplatin? - Authors' replyHironobu Hashimoto, Takuhiro Yamaguchi, Masakazu Abe
International Journal of Clinical Oncology|June 28, 2011
Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicinesTakashi Takeda, Takuhiro Yamaguchi, Nobuo Yaegashi
Drug Safety|March 23, 2011
The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008Nobuhiro Ooba, Takuhiro Yamaguchi, Kiyoshi Kubota
International Journal of Urology : Official Journal of the Japanese Urological Association|July 19, 2008
A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladderYukio Homma, Takuhiro Yamaguchi, Osamu Yamaguchi
[Nihon Koshu Eisei Zasshi] Japanese Journal of Public Health|March 8, 2005
[A survey on education of epidemiology and biostatistics in nursing programs at Japanese universities]Shiro Tanaka, Takuhiro Yamaguchi, Yasuo ohashi
Pageof 37